Pacira BioSciences, Inc.

Pacira BioSciences, Inc. is a pharmaceutical company specializing in the development and commercialization of non-opioid pain management and regenerative health solutions. The company's mission is to deliver innovative, non-opioid pain therapies to transform the lives of patients, aiming to redefine the role of opioids as rescue therapy only. Its corporate headquarters are located in Tampa, Florida.

Pacira's product portfolio includes three commercial-stage non-opioid treatments: EXPAREL (bupivacaine liposome injectable suspension), a long-acting local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), an extended-release intra-articular injection for osteoarthritis knee pain; and iovera, a handheld cryoanalgesia device for drug-free pain control. These products leverage the company's proprietary multivesicular liposome (pMVL) technology for sustained drug release. Pacira primarily serves healthcare practitioners and institutions, including hospitals, ambulatory surgical centers, and orthopedic clinics, within the United States.

In recent developments, Pacira BioSciences reported total revenues of $177.4 million for the first quarter of 2026, marking a 5% increase year-over-year. The company is actively advancing its pipeline, having completed enrollment in a Phase 3 study for ZILRETTA in shoulder osteoarthritis and progressing a Phase 2 study for PCRX-201, a gene therapy for knee osteoarthritis, with top-line data anticipated later in 2026. Frank D. Lee serves as the Chief Executive Officer and Director. Pacira maintains a market leadership position in non-opioid pain management, driven by its "5x30 strategy" launched in January 2025, which aims to treat over 3 million patients annually and achieve double-digit product revenue growth by 2030.